Independent risk factors predicting acute graft rejection in cardiac transplant recipients treated by triple drug immunosuppression.

[1]  G. Laufer,et al.  Incidence and severity of acute cardiac allograft rejection with two different low-dose cyclosporine maintenance protocols. , 1988, The Annals of thoracic surgery.

[2]  E. Blackstone,et al.  Analysis of morbid events and risk factors for death after cardiac transplantation. , 1988, Journal of the American College of Cardiology.

[3]  G. Persijn,et al.  EVIDENCE THAT THE DIFFERENCE IN KIDNEY GRAFT SURVIVAL IN DRw6+ AND DRw6− RECIPIENTS MAY BE EXPLAINED BY A BLOOD TRANSFUSION POLICY THAT IS DISADVANTAGEOUS FOR DRw6+ RECIPIENTS , 1987, Transplantation.

[4]  P. Reddy,et al.  Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. , 1987, Circulation.

[5]  M. Suthanthiran,et al.  Effect of immunosuppressants on OKT3 associated T cell activation: clinical implications. , 1987, Kidney international.

[6]  G. Deeb,et al.  Antithymocyte gamma globulin, low-dosage cyclosporine, and tapering steroids as an immunosuppressive regimen to avoid early kidney failure in heart transplantation. , 1987, The Journal of heart transplantation.

[7]  Kaye Mp,et al.  The Registry of the International Society for Heart Transplantation: fourth official report--1987. , 1987, Clinical transplants.

[8]  D. Renlund,et al.  Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. , 1987, The American journal of medicine.

[9]  A. Khaghani,et al.  The influence of HLA matching in cardiac allograft recipients receiving cyclosporine and azathioprine. , 1987, Transplantation proceedings.

[10]  G Opelz,et al.  CORRELATION OF HLA MATCHING WITH KIDNEY GRAFT SURVIVAL IN PATIENTS WITH OR WITHOUT CYCLOSPORINE TREATMENT: FOR THE COLLABORATIVE TRANSPLANT STUDY , 1985, Transplantation.

[11]  N. Isakov,et al.  GENETIC CONTROL OF VARIABILITY IN RESPONSES TO CLASS‐I‐ANTIGEN‐DISPARATE THYROID GRAFTS , 1985, Transplantation.

[12]  J. Fabre,et al.  Massive induction of donor-type class I and class II major histocompatibility complex antigens in rejecting cardiac allografts in the rat , 1985, The Journal of experimental medicine.

[13]  B. Myers,et al.  Cyclosporine-associated chronic nephropathy. , 1984, The New England journal of medicine.

[14]  S. Fuggle,et al.  THE DETAILED DISTRIBUTION OF MHC CLASS II ANTIGENS IN NORMAL HUMAN ORGANS , 1984, Transplantation.

[15]  S. Fuggle,et al.  THE DETAILED DISTRIBUTION OF HLA‐A, B, C ANTIGENS IN NORMAL HUMAN ORGANS , 1984, Transplantation.

[16]  J. Howard,et al.  Genetic control of transplant rejection. , 1982, Transplantation.

[17]  J. D. De Mey,et al.  OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. , 1980, Journal of immunology.

[18]  D. Renlund,et al.  Use of OKT3 monoclonal antibody in heart transplantation: Review of the initial experience , 1988 .

[19]  B. Kahan.  Immunosuppressive therapy with cyclosporine for cardiac transplantation. , 1987, Circulation.

[20]  R. Schwartz.  Immune response (Ir) genes of the murine major histocompatibility complex. , 1986, Advances in immunology.

[21]  P. Spratt,et al.  Effectiveness of minimal dosage cyclosporine in limiting toxicity and rejection. , 1986, The Journal of heart transplantation.